Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, Alopecia Areata patients were generally knowledgeable about their condition, believed it was due to genetic or health factors, and experienced significant anxiety and depression affecting their quality of life.

This report describes a rare case of papular atrichia in a 4-year-old girl, highlighting the absence of effective treatment to stimulate hair growth for this condition.

This study reports a notable case of a patient with psoriatic arthritis and alopecia universalis who experienced significant improvement in both conditions after treatment with the JAK1 selective inhibitor upadacitinib, suggesting its potential efficacy for alopecia universalis, especially in cases involving inflammatory arthritis.

This review discusses recent advances in understanding and treating alopecia areata, emphasizing the ongoing challenges and unmet needs in disease management; it reports no new clinical findings.

This study observed that most pediatric dermatologists prefer class 1 and 2 topical corticosteroids as first-line treatments for pediatric alopecia areata, with increasing use of JAK inhibitors as second-line therapy.

Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.

In this study using a mouse model, RIPK1 inhibitors were found to delay the onset of alopecia areata, reduce immune cell numbers in affected skin, and increase hair length, indicating a potential therapeutic role in preventing alopecia areata.

This review highlights significant advances in understanding and treating Alopecia Areata, emphasizing the effectiveness of JAK inhibitors like baricitinib, ritlecitinib, and deuruxolitinib for systemic treatment, while also noting ongoing research into new therapeutic approaches such as stem cell therapy and energy-assisted drug delivery.

This narrative review highlights the shared immunopathogenesis of alopecia areata and atopic dermatitis and discusses approved and investigational therapies that target common pathways, suggesting a future for personalized treatment strategies.

This content contains no study findings or new results, instead referring only to statistical methods and figure captions.

This paper discusses alopecia areata, its autoimmune nature, factors influencing susceptibility, diagnostic challenges, and treatment limitations, concluding that no current therapy is curative or preventive; it reports no new clinical results.

This research reported that AKR1C enzyme expression, particularly AKR1C4, in scalp sebaceous glands decreases with age, suggesting potential age-related changes in androgen metabolism affecting hair follicle health. Additionally, sulforaphane treatment increased AKR1C expression in related cell types.

This study found that compound 3 derived from aza-bicyclo-carboxylic acid may exert a cardioprotective effect by reducing infarction area in myocardial ischemia-reperfusion injury, potentially involving A1-adenosine receptor activation and changes in cAMP levels.

Measuring the variety in hair thickness can help diagnose male pattern baldness in Korean men.

This report observed that a patient with alopecia areata, resistant to ritlecitinib, experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential in treating ritlecitinib-resistant cases and suggesting personalized treatment strategies in managing alopecia areata.

This study developed a new neural network model (AA-GAN-AB-MTEDeep) to enhance Alopecia Areata classification using synthetic scalp images, achieving an accuracy of 96.94%.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

This research discusses the complex immune pathogenesis of alopecia areata and highlights the success of Jak inhibitors and IL-4Rα antagonists, while IL-17A and PDE4 inhibitors showed limited efficacy; controlled trials are advocated to better understand cytokine involvement.

This study found that ILK deficiency disrupts hair follicle development by impairing cell polarity and laminin-511 assembly, but these defects can be partially reversed with exogenous laminin-511.

This review reports that combining adipose-derived stem cells with decellularized extracellular matrix enhances tissue repair by improving scaffold biological activity and promoting angiogenesis, integration, and functional regeneration across various tissues, while addressing challenges in traditional transplantation methods.

This study observed that alopecia areata patients experience significant psychosocial issues, with a high prevalence of anxiety, depression, and impaired quality of life across symptoms, functioning, and emotions.

This case study reports that a man with severe patch-type alopecia areata initially responded to baricitinib treatment but experienced a relapse despite ongoing therapy.

Baricitinib stops hair loss and promotes regrowth in alopecia areata.

This study reports a unique case of identical twins experiencing alopecia areata at the same time, suggesting potential environmental triggers for this polygenic autoimmune condition.

This study found that immune-mediated destruction of bulge stem cells is a key factor in the alopecia observed in AE mice, suggesting it as a model for studying primary cicatricial alopecias, particularly lichen planopilaris.

This review discusses the evidence supporting Janus kinase inhibitors for alopecia areata and highlights ongoing optimism as phase 3 trials begin, with no new clinical results reported.

This study introduced the KRDQN predictive framework, which outperformed existing methods in predicting adverse drug reactions and provided interpretable insights into drug mechanisms, aiding pharmacovigilance and clinical decision-making.

This study found that JAK1 and JAK3 inhibitors effectively reversed alopecia in a mouse model of AA by reducing skin inflammation, while JAK2 inhibition did not promote hair regrowth.

This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.